Innate Pharma (IPHA) Capital Expenditures (2019 - 2024)
Historic Capital Expenditures for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$417820.8.
- Innate Pharma's Capital Expenditures fell 1063.56% to -$417820.8 in Q4 2024 from the same period last year, while for Dec 2024 it was -$1.1 million, marking a year-over-year increase of 3373.14%. This contributed to the annual value of $417820.8 for FY2024, which is 1063.56% up from last year.
- As of Q4 2024, Innate Pharma's Capital Expenditures stood at -$417820.8, which was down 1063.56% from -$377654.9 recorded in Q4 2023.
- Innate Pharma's 5-year Capital Expenditures high stood at -$289025.2 for Q2 2021, and its period low was -$1.1 million during Q4 2020.
- In the last 5 years, Innate Pharma's Capital Expenditures had a median value of -$448163.8 in 2022 and averaged -$573147.2.
- In the last 5 years, Innate Pharma's Capital Expenditures skyrocketed by 5176.44% in 2021 and then plummeted by 5506.05% in 2022.
- Innate Pharma's Capital Expenditures (Quarter) stood at -$1.1 million in 2020, then increased by 1.73% to -$1.1 million in 2021, then soared by 48.64% to -$545832.3 in 2022, then soared by 30.81% to -$377654.9 in 2023, then decreased by 10.64% to -$417820.8 in 2024.
- Its last three reported values are -$417820.8 in Q4 2024, -$377654.9 for Q4 2023, and -$336477.6 during Q2 2023.